Conjunctival sac microbiome status and the use of picloxidine dihydrochloride in children with infectious conjunctivitis

The surface of the eyeball presents a unique microbiocynosis, which is composed of various bacteria including viruses. Proceeding in the body itself. Infectious conjunctivitis in children is one of the most frequent and widespread processes, which determines the relevance of this problem. Inflammatory diseases can be both independent diseases and a reflection of negative processes of the eye.

Aim. To evaluate the efficacy of picloxidine dihydrochloride in the composition 0.05% eye drops in the treatment of infectious conjunctivitis in children according to the results of conjunctival cavity microbiosis study by chromatography-mass spectrometry.

Materials and methods. The study included 61 patients (104 eyes) with infectious conjunctivitis aged from 1 to 9 years (5.02 ± 0.25). The state of conjunctival cavity microbiocenosis was studied in all patients before treatment by chromato-mass spectrometry. All patients were prescribed instillations of picloxidine dihydrochloride as a part of eye drops 0.05% into conjunctival cavity with the frequency of 4 times a day.

Results. A more severe course of conjunctivitis was recorded in children with less Bifidobacterium spp.

Discussion. Dysbiosis of conjunctival sac microbiome reflects the reserve potential of the immunity of the bulbar conjunctiva. Due to emergence of 4 types of pathogenic microflora, cytomegalovirus (20% of patients) and a decrease in all types of normal flora, a significant increase in opportunistic microorganisms (12 types), 2 to 59.5-fold increase on average is recorded, and every 3^rd patient is diagnosed with an increased titer of total endotoxin, which indicates the decreased reserve potential of the immunity of the bulbar conjunctiva.

Conclusion. Antiseptic with picloxidine dihydrochloride 0.05% in the eye drops Piktorid-SOLOpharm is a broad spectrum drug in the treatment of infectious conjunctivitis in children without significant side effects.

1. Kochergin SА, Tchernakova GM, Klescheva EA, Shapoval IM, Mezentseva MV. Immunity of eye-bulbe and conjunctive microflora. Russian Journal of Infection and Immunity. 2012;2(3):635–644. (In Russ.) https://doi.org/10.15789/2220-7619-2012-3-635-644.

2. Leger AJ, Desai JV, Drummond RA, Kugadas A, Almaghrabi F, Silver P et al. An Ocular Commensal Protects against Corneal Infection by Driving an Interleukin-17 Response from Mucosal γδ T Cells. Immunity. 2017;47(1):148–158. https://doi.org/10.1016/j.immuni.2017.06.014.

3. Doan T, Akileswaran L, Andersen D, Johnson B, Ko N, Shrestha A et al. Paucibacterial Microbiome and Resident DNA Virome of the Healthy Conjunctiva. Invest Ophthalmol Vis Sci. 2016;57(13):5116–5126. https://doi.org/10.1167/iovs.16-19803.

4. Polyakova АS, Tatochenko VK. Once again about the term “viral-bacterial infection”. Meditsinskiy sovet. 2015;(14):30–35. (In Russ.) https://doi.org/10.21518/2079-701X-2015-14-30-35.

5. Harbarth S, Samore MH. Antimicrobial resistance determinants and future control. Emerg Infect Dis. 2005;11(6):798–801. https://doi.org/10.3201/eid1106.050167.

6. Shimizu Y, Toshida H, Honda R, Ohta T, Asada Y, Murakami A. Prevalence of drug resistance and culture-positive rate among microorganisms isolated from patients with ocular infections over a 4-year period. Clin Ophthalmol. 2013;7:695–702. https://doi.org/10.2147/OPTH.S43323.

7. Mishra SK, Basukala P, Basukala O, Parajuli K, Pokhrel BM, Rijal BP. Detection of biofilm production and antibiotic resistance pattern in clinical isolates from indwelling medical devices. Curr Microbiol. 2015;70(1):128–134. https://doi.org/10.1007/s00284-014-0694-5.

8. Kim SJ, Toma HS. Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitudinal controlled study of patients undergoing intravitreal injections. Arch Ophthalmol. 2011;129(9):1180–1188. https://doi.org/10.1016/j.ophtha.2010.12.014.

9. Ozkan J, Willcox MD. The Ocular Microbiome: Molecular Characterization of a Unique and Low Microbial Environment. Curr Eye Res. 2019;44(7):685–694. https://doi.org/10.1080/02713683.2019.1570526.

10. Budzinskaia MV, Strakhovskaya MG, Andreeva IV, Khalatyan AS. Conjunctival microflora and its antibiotic sensitivity after serial intravitreal injections. Vestnik Oftalmologii. 2019;135(5):135–140. (In Russ.) https://doi.org/10.17116/oftalma2019135052135.

11. Khalatyan AS, Budzinskaya MV, Kholina EG, Strakhovskaya MG, Kolyshkina NA, Kovalenko IB, Zhukhovitsky VG. Sensitivity of antibiotic resistant coagulase-negative staphylococci to antiseptic piсloxydin. Journal of Clinical Practice. 2020;11(1):42–48. (In Russ.) https://doi.org/10.17816/clinpract17543.

12. Kosyakova KG, Esaulenko NB, Kameneva OA, Kazakov SP, Dubinina AY, Mezina EY, Zaitsev AA. Prevalence of Carbapenemase Genes, qacE, qacEΔ1 and cepA in Multidrug-Resistant Gram-Negative Bacteria with Different Susceptibility to Chlorhexidine. Epidemiologiya i Vaktsinoprofilaktika. 2020;19(5):49–60. (In Russ.) https://doi.org/10.31631/2073-3046-202019-5-49-60.

13. Мороз БТ, Миргородская ЛВ, Перькова НИ, Рохваргер ИС. Разработка и внедрение в практику новых лекарственных форм отечественного антисептика мирамистина. В: Первая международная конференция «Клинические исследования лекарственных средств: материалы конференции. Москва, 20–22 ноября. 2001 г. М.: Святигор; 2002. 191 с.

14. Кривошеин ЮС (ред.). Мирамистин. М.; 2004. 625 с.

15. Амирова ЗК, Арчаков АИ, Биктимиров ЭФ. Химический анализ в медицинской диагностике. М.: Наука; 2010. 503 с.

16. Platonova AG, Osipov GA, Boyko NB, Kirillova NV, Rodionov GG. Chromatography-mass spectrometric study of microbial fatty acids in human biological fluids and their clinical significance. Klinichescheskaya Laboratornaya Diagnostika. 2015;60(12):46–55. (In Russ.) https://clinlabdia.ru/article/hromato-mass-spektrometricheskoe-iss.